Recombinant activated factor VII in clinical practice: a 2014 update

Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital hemophilia and inhibitors. Due to the initial success in this clinical setting, its use has been extended to other coagulopathies characterized by impaired thrombin generation, i....

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of thrombosis and thrombolysis Ročník 39; číslo 2; s. 235 - 240
Hlavní autoři:	Franchini, Massimo, Crestani, Silvia, Frattini, Francesco, Sissa, Cinzia, Bonfanti, Carlo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Boston Springer US 01.02.2015 Springer Nature B.V
Témata:	Blood Coagulation - drug effects Cardiology Clinical Trials as Topic Factor VII Deficiency - drug therapy Factor VIIa - pharmacology Hematology Hemophilia A - drug therapy Hemostatics - pharmacology Humans Medicine Medicine & Public Health Recombinant Proteins - pharmacology Thrombasthenia - drug therapy FVII deficiency Recombinant activated FVII rFVIIa NovoSeven Hemophilia Acquired FVIII inhibitors Glanzmann’s thrombasthenia
ISSN:	0929-5305, 1573-742X, 1573-742X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!